Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 6/20 | 0.58 |
| ▸ | MEN1 | O00255 | 6/20 | 0.58 |
| ▸ | KMT2A | Q03164 | 6/20 | 0.58 |
| ▸ | KDM4E | B2RXH2 | 5/20 | 0.58 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.58 |
| ▸ | NPSR1 | Q6W5P4 | 5/20 | 0.53 |
| ▸ | RAB9A | P51151 | 5/20 | 0.53 |
| ▸ | HTT | P42858 | 4/20 | 0.53 |
| ▸ | GALR2 | O43603 | 1/20 | 0.53 |
| ▸ | MITF | O75030 | 1/20 | 0.53 |
| ▸ | GLA | P06280 | 1/20 | 0.53 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.53 |
| ▸ | PKM | P14618 | 1/20 | 0.53 |
| ▸ | NPC1 | O15118 | 4/20 | 0.53 |
| ▸ | HKDC1 | Q2TB90 | 1/20 | 0.53 |
| ▸ | POLB | P06746 | 4/20 | 0.49 |
| ▸ | HPGD | P15428 | 2/20 | 0.47 |
| ▸ | NTSR1 | P30989 | 1/20 | 0.47 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.47 |
| ▸ | PAX8 | Q06710 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5094094 | 0.85 | MAPT (0.43) | MAPTMEN1KMT2AKDM4EALDH1A1 | |
| SCHEMBL12270022 | 0.80 | L3MBTL1 (0.53) | MAPTMEN1KMT2AKDM4EALDH1A1 | |
| SCHEMBL29542490 | 0.79 | MAPT (0.40) | MAPTMEN1KMT2AKDM4EALDH1A1 | |
| SCHEMBL24725062 | 0.76 | MEN1 (0.50) | MAPTMEN1KMT2AALDH1A1NPSR1 | |
| SCHEMBL887129 | 0.74 | HTT (0.54) | MAPTMEN1KMT2AKDM4EALDH1A1 | |
| SCHEMBL1333179 | 0.74 | HTT (0.54) | MAPTMEN1KMT2AKDM4EALDH1A1 | |
| SCHEMBL887130 | 0.74 | CREBBP (0.55) | MAPTMEN1KMT2AKDM4EALDH1A1 | |
| SCHEMBL5567714 | 0.74 | MAPT (1.00) | MAPTMEN1KMT2AKDM4EALDH1A1 | |
| SCHEMBL4207590 | 0.73 | CREBBP (0.63) | MEN1KMT2AKDM4EALDH1A1RAB9A | |
| SCHEMBL13806317 | 0.73 | POLB (0.54) | MAPTMEN1KMT2AKDM4EALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 67 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-108947890-B | Method for preparing disubstituted 4-aminocarbazole compound | 台州学院 | 2020-08-04 | — | — | CN | disclosed |
| US-10689409-B2 | Amino compounds for treatment of complement mediated disorders | ACHILLION PHARMACEUTICALS, INC. (US) | 2020-06-23 | — | — | US | disclosed |
| US-10660876-B2 | Amino compounds for treatment of medical disorders | ACHILLION PHARMACEUTICALS, INC. (US) | 2020-05-26 | — | — | US | disclosed |
| US-10428094-B2 | Amide compounds for treatment of complement mediated disorders | ACHILLION PHARMACEUTICALS, INC. (US) | 2019-10-01 | — | — | US | disclosed |
| US-10370394-B2 | Carbamate, ester, and ketone compounds for treatment of complement mediated disorders | ACHILLION PHARMACEUTICALS, INC. (US) | 2019-08-06 | — | — | US | disclosed |
| US-20190144473-A1 | AMINO COMPOUNDS FOR TREATMENT OF COMPLEMENT MEDIATED DISORDERS | ACHILLION PHARMACEUTICALS, INC. (US) | 2019-05-16 | — | — | US | disclosed |
| US-10189869-B2 | Amino compounds for treatment of complement mediated disorders | ACHILLION PHARMACEUTICALS, INC. (US) | 2019-01-29 | — | — | US | disclosed |
| US-10138225-B2 | Amide compounds for treatment of medical disorders | ACHILLION PHARMACEUTICALS, INC. (US) | 2018-11-27 | — | — | US | disclosed |
| US-20180177761-A1 | AMINO COMPOUNDS FOR TREATMENT OF MEDICAL DISORDERS | ACHILLION PHARMACEUTICALS, INC. (US) | 2018-06-28 | — | — | US | disclosed |
| US-10005802-B2 | Amide compounds for treatment of complement mediated disorders | ACHILLION PHARMACEUTICALS, INC. (US) | 2018-06-26 | — | — | US | disclosed |
| US-20150239893-A1 | Amide Compounds for Treatment of Complement Mediated Disorders | ACHILLION PHARMACEUTICALS, INC. (US) | 2015-08-27 | — | — | US | disclosed |
| US-20150239893-A1 | Amide Compounds for Treatment of Complement Mediated Disorders | ACHILLION PHARMACEUTICALS, INC. (US) | 2015-08-27 | — | — | US | disclosed |
| US-20150239894-A1 | Amino Compounds for Treatment of Complement Mediated Disorders | ACHILLION PHARMACEUTICALS, INC. (US) | 2015-08-27 | — | — | US | disclosed |
| US-20150239894-A1 | Amino Compounds for Treatment of Complement Mediated Disorders | ACHILLION PHARMACEUTICALS, INC. (US) | 2015-08-27 | — | — | US | disclosed |
| US-20150239837-A1 | Factor D Inhibitors Useful for Treating Inflammatory Disorders | ACHILLION PHARMACEUTICALS, INC. (US) | 2015-08-27 | — | — | US | disclosed |
| US-20150239919-A1 | Carbamate, Ester, and Ketone Compounds for Treatment of Complement Mediated Disorders | ACHILLION PHARMACEUTICALS, INC. (US) | 2015-08-27 | — | — | US | disclosed |
| US-20150239919-A1 | Carbamate, Ester, and Ketone Compounds for Treatment of Complement Mediated Disorders | ACHILLION PHARMACEUTICALS, INC. (US) | 2015-08-27 | — | — | US | disclosed |
| US-20150239893-A1 | Amide Compounds for Treatment of Complement Mediated Disorders | ACHILLION PHARMACEUTICALS, INC. (US) | 2015-08-27 | — | — | US | disclosed |
| US-20150239894-A1 | Amino Compounds for Treatment of Complement Mediated Disorders | ACHILLION PHARMACEUTICALS, INC. (US) | 2015-08-27 | — | — | US | disclosed |
| US-20150166641-A1 | Compositions and Methods for the Removal of Biofilms | UNIV SOUTHERN CALIFORNIA (US) | 2015-06-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (14 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10138225-B2 | Amide compounds for treatment of medical disorders | CFD, TFPI, CFH | MAPT 3750/4885MEN1 341/4885KMT2A 4040/4885 |
| US-20190144473-A1 | AMINO COMPOUNDS FOR TREATMENT OF COMPLEMENT MEDIATED DISORDERS | CFD, TFPI, C9 | MAPT 3981/4885MEN1 695/4885KMT2A 4197/4885 |
| US-10189869-B2 | Amino compounds for treatment of complement mediated disorders | CFD, TFPI, C9 | MAPT 3981/4885MEN1 695/4885KMT2A 4197/4885 |
| US-20150239837-A1 | Factor D Inhibitors Useful for Treating Inflammatory Disorders | CFD, TFPI, TFPI2 | MAPT 3338/4885MEN1 1357/4885KMT2A 4720/4885 |
| US-10370394-B2 | Carbamate, ester, and ketone compounds for treatment of complement mediated disorders | CFD, C9, CFH | MAPT 3681/4885MEN1 823/4885KMT2A 2789/4885 |
| US-10005802-B2 | Amide compounds for treatment of complement mediated disorders | CFD, TFPI, CFH | MAPT 4161/4885MEN1 354/4885KMT2A 3812/4885 |
| US-20150239894-A1 | Amino Compounds for Treatment of Complement Mediated Disorders | CFD, TFPI, C9 | MAPT 3981/4885MEN1 695/4885KMT2A 4197/4885 |
| US-10660876-B2 | Amino compounds for treatment of medical disorders | CFD, CFH, F12 | MAPT 3697/4885MEN1 133/4885KMT2A 4309/4885 |
| US-10428094-B2 | Amide compounds for treatment of complement mediated disorders | CFD, TFPI, C9 | MAPT 3961/4885MEN1 1011/4885KMT2A 4064/4885 |
| US-20150166641-A1 | Compositions and Methods for the Removal of Biofilms | FCGR3B, FGB, CD47 | MAPT 2225/4885MEN1 2004/4885KMT2A 4429/4885 |
| US-20150239893-A1 | Amide Compounds for Treatment of Complement Mediated Disorders | CFD, TFPI, C9 | MAPT 3961/4885MEN1 1011/4885KMT2A 4064/4885 |
| US-20180177761-A1 | AMINO COMPOUNDS FOR TREATMENT OF MEDICAL DISORDERS | CFD, CFH, F12 | MAPT 3697/4885MEN1 133/4885KMT2A 4309/4885 |
| US-10689409-B2 | Amino compounds for treatment of complement mediated disorders | CFD, TFPI, C9 | MAPT 3981/4885MEN1 695/4885KMT2A 4197/4885 |
| US-20150239919-A1 | Carbamate, Ester, and Ketone Compounds for Treatment of Complement Mediated Disorders | CFD, C9, CFH | MAPT 3681/4885MEN1 823/4885KMT2A 2789/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.